CYDY

Leronlimab (PRO 140)

COVID-19

Interim Analysis

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Leronlimab (PRO 140) in COVID - Interim Analysis

  • ClinicalTrial.gov (NCT04347239): Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

  • ClinicalTrial.gov (NCT04343651): Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19


WHAT IS THE CATALYST EVENT?

  • Interim Analysis


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), with potential activity as a human immunodeficiency virus (HIV) entry blocker and potential protective activity against graft-versus-host disease (GvHD). Upon administration, leronlimab targets and binds to CCR5 expressed on T cells. This blocks HIV cell entry, which prevents HIV infection and/or reduces HIV viral load. In addition, blocking CCR5 by leronlimab decreases CCR5-mediated signaling and the CCR5-induced migration of donor cells into tissues after an allogeneic hematopoietic cell transplantation (HCT). Blocking CCR5 may therefore prevent or reduce GvHD. CCR5, a co-receptor needed for HIV cell entry, plays a key role in immunomodulation. Expressed on monocytes, activated T cells and dendritic cells (DCs), CCR5 can regulate chemotaxis. Lymphocyte trafficking via chemokine receptors, such as CCR5, and recruitment to target organs, plays a critical role in alloreactive responses (Learn more - National Cancer Institute)

Updated by HC

#CYDY, #Leronlimab, #PRO140, #CCR5, #COVID, #Antibody

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

CYDY - CytoDyn Receives Positi...

#CYDY "announced today recommendations from the Data Safety Monitoring Committee (DSMC) following its review of the interim analysis of the Company’s Phase 2b/3 registrational trial in patients with s...

CYDY - Hold Webcast on October...

#CYDY "announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Se...

CYDY - Appoints Chiral Pharma ...

CYDY "announced today its appointment of Chiral Pharma Corporation, a subsidiary of Philippine New Marketlink Pharmaceutical Corporation (NMPC), to register leronlimab (PRO 140) for potential approval...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon